Castle Creek Biosciences

Exton, United States Founded: 2018 • Age: 8 yrs
Gene therapy platform for rare disease treatments is developed.

About Castle Creek Biosciences

Castle Creek Biosciences is a Healthcare company based in Exton (United States) founded in 2018. Gene therapy platform for rare disease treatments is developed. Castle Creek Biosciences has raised $192.8 million across 4 funding rounds from investors including Fidelity Investments, Paragon Biosciences and Horizon Tech Finance. The company has 41 employees. Its focus areas include Life Sciences, Rare Diseases, Drugs and Dermatological Diseases. Its legal entity is CASTLE CREEK BIOSCIENCES, LLC. Its competitors include Ironwood Pharma, Castle Creek Pharma and VeraDermics; 3 of its 3 listed competitors have raised funding.

Company details

Castle Creek Biosciences was founded in 2018 and is headquartered in Exton, United States. A gene therapy platform based on autologous fibroblasts derived from patient skin cells is offered for rare skin and connective tissue disorders, including epidermolysis bullosa and localized scleroderma. Clinical development includes FCX-007 in phase 3 trials, with FCX-013 and CCP-020 in phase 2. Operations focus on dermatology and related rare disease areas.

  • Headquarters Exton, United States
  • Employees 41
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website castlecreekbio.com
  • Social LinkedIn X Facebook
  • Legal Name Castle Creek Biosciences, Llc
Operational Areas
Key Metrics
  • Total Equity Funding
    $192.8M (USD)

    in 4 rounds

  • Latest Funding Round
    $112.8M (USD), Series D

    Jan 2022

  • Investors
  • Employee Count
    41

Funding Insights of Castle Creek Biosciences

Castle Creek Biosciences has successfully raised a total of $192.8M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $112.8 million completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $192.8M
  • Total Rounds 4
  • Last Round Series D β€” $112.8M
  • First Round $20M

    (Mar 2020)

  • Investors Count 4

All 4 funding rounds of Castle Creek Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jan 2022$112.8MSeries D–Fidelity Investments, Valor Equity Partners
–
Jun 2021$25MSeries C––
–
Mar 2020$55MSeries C–Paragon Biosciences
Mar 2020$20MDebt – Conventional––
Valuation history

4 investors in total: 4 institutional.

Investors in Castle Creek Biosciences

Castle Creek Biosciences has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Paragon Biosciences and Horizon Tech Finance.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Private equity firm
valorep.comChicago, United States
Structured debt is provided to life sciences and technology firms.
2004horizontechfinance.comFarmington, United States
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms
1946fidelity.comBoston, United States
Advisory services are provided to healthcare companies.
2010paragonbiosci.comChicago, United States
Premium access

Investor details for Castle Creek Biosciences

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Castle Creek Biosciences

12 people are tracked at Castle Creek Biosciences (6 in leadership, 1 in board & advisors, 5 in team); the tracked headcount is 41.

NameRoleGroup
Matthew Gantz
Chairman & CEOLeadership
Mayo Pujols
Chief Operating OfficerLeadership
Matthew Crabtree
Senior Director, FinanceLeadership
David Chu
Chief Medical OfficerLeadership
Karen Casey
Director, Corporate CommunicationsLeadership
Shelby Stevens
Director Of ManufacturingLeadership
M. Peter Marinkovich
Scientific AdvisorBoard & advisors
Savita Mehra
AVP, Quality AssuranceTeam
Forrest Jacobs
Desktop Support ManagerTeam
Lauren Stephenson
Quality Assurance ManagerTeam
Nicholas Bastian
Manufacturing SupervisorTeam
Katie Dungca
Supervisor PCR LabTeam
Premium access

Complete people profiles for Castle Creek Biosciences

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Castle Creek Biosciences

3 dated milestones of Castle Creek Biosciences across 4 years, from founding to its latest funding, stage changes and deals.

  1. Founded Castle Creek Biosciences is founded.
  2. Funding First funding round of $20.0M.
  3. Funding Latest funding round, Series D, of $112.8M.

Competitors of Castle Creek Biosciences

Castle Creek Biosciences has 3 listed competitors in our database, 3 of them funded. They include Ironwood Pharma, Castle Creek Pharma and VeraDermics.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
ironwoodpharma.com1998Cambridge, United States$206.25M220
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
castlecreekpharma.com2015Basking Ridge, United States$663.15M72
Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders
veradermics.com2020San Antonio, United States$262.71M
Drug-delivery platforms for pediatric wart treatments are developed.
Premium access

Detailed competitors of Castle Creek Biosciences

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Castle Creek Biosciences

The website of Castle Creek Biosciences (castlecreekbio.com) receives about 2.8K visits a month.

  • Monthly visits
    2.8K

    ▲ 37.9% vs previous month

Top companies in Rare Diseases

3 companies that operate in the same segment as Castle Creek Biosciences (Rare Diseases) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Gene therapies for rare diseases including retinal dystrophies are developed.
2013Philadelphia, Pennsylvania, United StatesUSD 82.8 MUSD 64.73 M822
Therapeutics for genetic diseases are developed through targeted interventions.
2015Palo Alto, California, United StatesUSD 434.2 MUSD 502.08 M730
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Castle Creek Biosciences

Premium access

Complete news archive for Castle Creek Biosciences

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Castle Creek Biosciences

Castle Creek Biosciences was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Castle Creek Biosciences is headquartered in Exton, United States. It is registered at Exton, Pennsylvania, United States.

Castle Creek Biosciences is a funded company, having raised a total of $192.8M across 4 funding rounds to date. The company's 1st funding round was a Series C of $55M, raised on Mar 2020.

Castle Creek Biosciences has 41 employees.

Castle Creek Biosciences was founded in 2018 and is headquartered in Exton, United States. A gene therapy platform based on autologous fibroblasts derived from patient skin cells is offered for rare skin and connective tissue disorders, including epidermolysis bullosa and localized scleroderma. Clinical development includes FCX-007 in phase 3 trials, with FCX-013 and CCP-020 in phase 2. Operations focus on dermatology and related rare disease areas.

Castle Creek Biosciences's top competitors include Ironwood Pharma, VeraDermics and Castle Creek Pharma.

Castle Creek Biosciences has 4 investors. Key investors include Fidelity Investments, Paragon Biosciences, Horizon Tech Finance, and Valor Equity Partners.

Castle Creek Biosciences operates through Castle Creek Biosciences, Llc.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available